Additionally, long-term studies are needed to evaluate the impact of SGLT2 inhibitors on liver fibrosis, cardiovascular risk, and overall survival to fully establish their therapeutic potential. The gene discussed is SLC5A2; the disease is Hepatic fibrosis.